FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure
pharmaphorum
FEBRUARY 25, 2022
. “While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure,” says Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research.
Let's personalize your content